DEF 14A: Actuate Therapeutics Sets Date for 2025 Annual Stockholders Meeting

Actuate Therapeutics announces its 2025 annual meeting of stockholders to be held virtually on May 22, 2025, to vote on director elections and the ratification of the independent accounting firm.

Summary

• Actuate Therapeutics, Inc. will hold its 2025 annual meeting of stockholders virtually on May 22, 2025, at 10:30 a.m. Eastern Daylight Time.
• Stockholders of record as of March 25, 2025, are entitled to vote.
• The meeting will address the election of three Class I directors for three-year terms expiring in 2028, the ratification of Crowe LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and any other business that may properly come before the meeting.
• The Board of Directors recommends voting FOR the election of the director nominees and FOR the ratification of Crowe LLP.
• Proxy materials are available online at www.proxyvote.com.
• Stockholders can vote online, by telephone, or by mail prior to the meeting, or during the virtual meeting.

Sentiment

Score: 7

Explanation: The document is a standard corporate communication, presenting factual information in a neutral tone. The sentiment is moderately positive as it reflects the company's ongoing operations and governance processes.

Positives

• The company is providing a virtual meeting option to facilitate stockholder attendance and participation.
• The Board is recommending experienced individuals for re-election as directors.
• The company is seeking stockholder ratification of its choice of independent auditor.

Risks

• The division of the Board into three classes with staggered three-year terms may delay or prevent a change of our Board or a change in control of our Company.
• The proxy statement notes that the directors may be removed only for cause by the affirmative vote of the holders of at least two-thirds of our outstanding voting stock then entitled to vote in an election of directors.

Future Outlook

The company plans to announce preliminary voting results at the Annual Meeting and report final voting results in a Current Report on Form 8-K to be filed with the SEC within four business days following the Annual Meeting.

Management Comments

• Daniel M. Schmitt, President and Chief Executive Officer, thanks stockholders for their ongoing support and continued interest in Actuate Therapeutics, Inc.

Industry Context

This is a standard proxy statement for a publicly traded company, outlining the matters to be voted on at the annual meeting, providing information about the nominees for director, and disclosing executive compensation and related party transactions.

Comparison to Industry Standards

• The structure and content of this proxy statement are consistent with industry standards for publicly traded companies in the United States.
• The company's corporate governance practices, such as having an audit committee, compensation committee, and nominating and corporate governance committee, align with Nasdaq listing requirements and SEC regulations.
• The disclosure of executive compensation and related party transactions is in line with SEC disclosure requirements.

Related Party Transactions

• From 2015 through 2024, we entered into various financing transactions in which the Bios Equity Affiliated Funds and the Kairos Venture Affiliated Funds participated.
• In August 2024, the Bios Equity Affiliated Funds purchased 500,000 shares of our common stock in the IPO at the initial public offering price of $8.00 per share.

Stakeholder Impact

• Shareholders are asked to vote on key governance matters, influencing the direction and oversight of the company.
• The outcome of the votes will impact the composition of the board and the selection of the company's auditor.

Next Steps

• Stockholders are encouraged to review the proxy materials and vote on the proposals.
• The company will hold the annual meeting on May 22, 2025, and announce the voting results.

Key Dates

Keywords

annual meeting, proxy statement, directors, stockholders, Crowe LLP, corporate governance, voting, Actuate Therapeutics